SEC 8-K and 6-K filings classified by Claude with reasoning, plus Form 4 insider transactions. Ingested from EDGAR’s filing stream in near-real time, reconciled overnight.
Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
Board report addressing shareholder approval of the renewal and restatement of the Company's authorised capital to EUR 100 million and the Board's authority to limit or suppress preferential subscription rights in future capital increases, presenting material implications for capital structure flexibility and potential shareholder dilution.
View raw filing on EDGAR →Susan Reisbord has been appointed President & Chief Executive Officer, effective October 1, 2026, representing a material change in the company's top executive leadership. While Gord Johnston's retirement as CEO is also disclosed, the principal action is Reisbord's appointment to the CEO role. The press release emphasizes this as a Board-led succession plan with continuity, and Reisbord's appointment would materially affect investor assessment of the company's leadership and strategic direction.
View raw filing on EDGAR →This exhibit is a formal Report of Voting Results from Satellos Bioscience Inc.'s annual shareholder meeting held June 17, 2026. It discloses the outcomes of two matters voted upon: (1) election of nine directors with detailed vote tallies for each nominee, and (2) appointment of PricewaterhouseCoopers LLP as auditor with 98.69% approval. This is a classic shareholder_vote_results disclosure required under National Instrument 51-102 and material to investors assessing board composition and auditor appointment.
View raw filing on EDGAR →The exhibit discloses equity compensation grants to directors, officers, employees, and consultants: 201,969 stock options at $2.30 per share and 266,035 restricted share units, approved by the Board on June 11, 2026, with three-year vesting schedules. While the press release also announces receipt of a $50,000 government grant for exploration (operational/financial), the substantive disclosure requiring classification under 8-K Item 5.02(e) standards is the equity award grant, which is material to investors assessing management incentive alignment and potential dilution.
View raw filing on EDGAR →HDFC Bank Limited has completed the issuance of USD 750 million senior unsecured bonds with a 5-year tenure (maturity June 24, 2031) and a coupon of 5.067% per annum. This is a material creation of a direct financial obligation disclosed under SEBI Listing Regulations Regulation 30, constituting a significant debt issuance that would affect a reasonable investor's assessment of the registrant's capital structure and financial position.
View raw filing on EDGAR →The 6-K discloses results of an extraordinary general meeting of shareholders held on June 17, 2026, where shareholders voted on and approved the election of two Standing Directors (Baek, Woo-Ki and Chun, Chan-Hyuk) and two Non-Standing Audit Committee Members (Jung, Do-Jin and Hwang, Jeong-Hwa), with detailed voting tallies showing approval percentages ranging from 97.4% to 99.1%. This is a classic shareholder_vote_results disclosure under Item 5.07 equivalent, and director elections are material governance events affecting the composition of the board.
View raw filing on EDGAR →This is a press release announcing 17EdTech's unaudited financial results for the first quarter of 2026, dated June 17, 2026. The exhibit discloses quarterly net revenues of RMB99.5 million (up 359% year-over-year), gross margin of 61.9%, and net loss of RMB19.4 million (down 37.4% year-over-year), along with detailed operating expense breakdowns and cash position. The disclosure includes management commentary and is accompanied by unaudited condensed consolidated financial statements and reconciliations of non-GAAP measures. This is a discrete earnings announcement, not a periodic financial report filing, and the results are material to investors assessing the company's operational performance and financial trajectory.
View raw filing on EDGAR →The 6-K discloses the final results of the 2026 Annual Meeting of Shareholders held on June 15, 2026, specifically the election of six directors (Michael Cricenti, Bo Hu, Peter R. Kellogg, Ruigang Li, Tao Wang, and Chunhua Yu) with detailed vote tallies showing shares for, against, abstained, and broker non-votes for each candidate. This is a classic shareholder_vote_results disclosure under Item 5.07 equivalent, and board composition is material to investors.
View raw filing on EDGAR →NOVONIX announced a material capital raising comprising an institutional placement of 129,334,163 ordinary shares at A$0.16 per share (a 31.2–33.3% discount to market prices) under ASX Listing Rule 7.1 placement capacity, together with a non-underwritten share purchase plan (SPP) offering up to 18,750,000 shares to eligible shareholders at the same price. The placement and SPP are expected to raise approximately A$23.7 million in aggregate, directed toward capital expenditure and production capacity expansion.
View raw filing on EDGAR →MagnaChip held its Annual Meeting on June 11, 2026, with shareholders voting on four proposals: election of four directors, advisory vote on named executive officer compensation, ratification of auditor EY Han Young, and approval of the Amended and Restated 2020 Equity and Incentive Compensation Plan. Final vote tallies and percentages for each proposal are disclosed.
View raw filing on EDGAR →This exhibit discloses comprehensive changes to Toyota's board of directors and executive structure effective June 17, 2026, including the appointment of Kenta Kon as President and Representative Director, Hiroki Nakajima and Yoichi Miyazaki as Executive Vice Presidents, and the transition of Koji Sato from Vice Chairman to a continued Vice Chairman role. The document also details organizational restructuring and CxO assignments. While multiple individual executive appointments occur, the disclosure is fundamentally a governance restructuring announcement that would materially affect investor assessment of leadership and strategic direction, warranting classification as a material governance event rather than discrete appointment/departure events.
View raw filing on EDGAR →Daniel J. Thoren, Executive Chairman and director, notified the Company on June 15, 2026 of his intention to step down from both positions effective immediately, with transition arrangements and continued compensation as a Strategic Advisor.
View raw filing on EDGAR →Jonathan W. Painter was appointed as Chairman of the Board of Directors, effective June 17, 2026, as disclosed in a press release accompanying the filing.
View raw filing on EDGAR →The disclosure announces completion of target enrollment in a Phase 2b clinical trial (MIST trial) for AP01, a lead product candidate. While this is a material clinical development milestone that would affect investor assessment of the company's pipeline progress and de-risking, it does not fit neatly into the standard taxonomy categories. The event is disclosed under Item 7.01 (Regulation FD Disclosure) rather than a dedicated Item, and represents clinical trial progress rather than earnings, M&A, executive changes, or other specifically enumerated event types.
View raw filing on EDGAR →The filing discloses a press release under Item 8.01 (Other Events) but provides no substantive detail about the content or nature of the announcement. Without access to Exhibit 99.1, the specific event cannot be determined. Given Verizon's size and the formal 8-K filing, the press release likely addresses a material matter, but the event type cannot be confidently classified without knowing its subject matter.
View raw filing on EDGAR →Smartbird amended its Securities Purchase Agreement to increase the aggregate principal amount of senior secured convertible notes from $50.0 million to $100.0 million, with conversion into Class A common stock at $4.00 per share, representing a material dilutive issuance of convertible securities.
View raw filing on EDGAR →Nadia Carlsten was appointed as President, Chief Executive Officer, Secretary, and director of Smartbird, Inc., effective June 18, 2026, bringing expertise in AI and advanced computing. The appointment included a substantial inducement grant of 1,532,379 RSUs outside the Company's stockholder-approved equity plan.
View raw filing on EDGAR →Smartbird amended its Certificate of Incorporation and Bylaws to change the company name to Smartbird, Inc., remove public benefit corporation status, and lower the stockholder quorum requirement from a majority to one-third, representing material governance and structural changes.
View raw filing on EDGAR →This is a clear disclosure of shareholder voting results from Shift4 Payments' Annual Meeting of Stockholders held on June 12, 2026, covering five proposals: election of three Class III directors (Sam Bakhshandehpour, Jonathan Halkyard, and Nancy Disman), ratification of PricewaterhouseCoopers LLP as auditor, advisory approval of named executive officer compensation, approval of an amended certificate of incorporation, and approval of the 2026 Employee Stock Purchase Plan. The filing presents detailed vote tallies for each proposal and confirms all items passed, which is material to investors' understanding of corporate governance and shareholder sentiment.
View raw filing on EDGAR →Lynne C. Fitzpatrick has been appointed as Chief Executive Officer of CME Group, effective on the later of March 1, 2027, or the 2026 10-K filing date, succeeding Terrence A. Duffy. Duffy will transition to Executive Chairman, and compensatory arrangements have been established for both executives as part of the planned succession.
View raw filing on EDGAR →AstroNova entered into an Agreement and Plan of Merger on June 16, 2026, whereby Orion Merger Parent, Inc. (affiliated with Arcline Investment Management LP) will acquire the Company for $29.00 per share in cash. The transaction is subject to shareholder approval and regulatory clearance under the HSR Act, with customary termination rights and a $9.648 million termination fee.
View raw filing on EDGAR →Harmonic completed the sale of its Video Business to Leone Media Inc. (MediaKind) for $145 million in cash on June 16, 2026, pursuant to a previously disclosed Asset Purchase Agreement.
View raw filing on EDGAR →Neven Haltmayer, Senior Vice President and General Manager of the Video Business, resigned effective June 16, 2026, after 20 years of service, in connection with the completion of the Video Business sale.
View raw filing on EDGAR →Boyd Group Services Inc. announced a cash dividend of C$0.156 per common share for Q2 2026, payable July 29, 2026 to shareholders of record on June 30, 2026. This is a straightforward dividend declaration, which is a material capital allocation event that affects shareholder value and is routinely disclosed in 6-K filings by foreign private issuers.
View raw filing on EDGAR →This 8-K Item 5.07 discloses the final results of votes at Boundless Bio's annual stockholder meeting held June 15, 2026, covering two proposals: election of Class II directors (James Christensen and Jennifer Lew) and ratification of KPMG LLP as independent auditor. The tabulated vote counts for each proposal are the core disclosure required under Item 5.07, making this a textbook shareholder vote results filing that is material to investors assessing board composition and audit oversight.
View raw filing on EDGAR →This is a classic Item 5.07 disclosure of shareholder meeting results. The filing reports voting outcomes on four proposals at the 2026 Annual Meeting held June 17, 2026: election of two Class III directors (Michael Landsittel and Cameron Turtle), Say-on-Pay advisory vote, Say-on-Frequency advisory vote, and auditor ratification. All proposals passed with strong majorities, and the Board determined to hold annual Say-on-Pay votes based on the voting results.
View raw filing on EDGAR →The filing discloses a notice of delinquency from NYSE Regulation on May 19, 2026, for failure to timely file the Form 10-Q, triggering Section 1007 procedures and subjecting the Company to potential suspension and delisting. Although the Company subsequently filed the Form 10-Q on June 12, 2026, and regained compliance by June 15, 2026, the core event disclosed under Item 3.01 is the delisting risk and the Company's path through the compliance remediation process. This is material to investors as it reflects a serious breach of listing standards and the threat of delisting, even though the immediate risk was cured before the 8-K filing date.
View raw filing on EDGAR →This 8-K Item 5.07 discloses the certified results of Alector's 2026 annual meeting of stockholders held on June 17, 2026, including voting outcomes for three proposals: election of Class II directors (Elizabeth Garofalo, Errol De Souza, and Kristine Yaffe), ratification of Ernst & Young LLP as independent auditor, and advisory approval of named executive officer compensation. The filing presents vote tallies (for, against, abstentions, broker non-votes) for each matter, which is the core disclosure required under Item 5.07 for shareholder meeting results.
View raw filing on EDGAR →Outset Medical entered into a material amendment to its purchasing agreement with HCA on June 14, 2026, committing HCA to purchase approximately $40 million in new Tablo Hemodialysis Systems from 2026 through 2028, representing a significant multi-year commercial commitment affecting the company's revenue pipeline.
View raw filing on EDGAR →Item 2.02 disclosure explicitly references a press release issued on June 17, 2026, and states that textual information from that press release is being furnished in connection with "Results of Operations and Financial Condition." This is the standard format for earnings release disclosures under Item 2.02, with the press release attached as Exhibit 99.1.
View raw filing on EDGAR →ImageneBio held its Annual Meeting on June 16, 2026, with shareholders voting on three proposals: election of two Class II directors (David P. Bonita and Joseph P. Slattery), ratification of PricewaterhouseCoopers LLP as independent auditor, and approval of the 2025 Amended Equity Incentive Plan.
View raw filing on EDGAR →The Company entered into an underwriting agreement on June 15, 2026, to offer and sell 14,000,000 shares of common stock through a forward sale mechanism, with an additional 2,100,000 shares subject to an underwriter option. This is a material equity issuance that will dilute existing shareholders. Although structured as a forward sale (with settlement expected by June 16, 2027), the Company will receive net proceeds and contribute them to its operating partnership for acquisitions and general corporate purposes, making this a dilutive capital raise transaction.
View raw filing on EDGAR →Stacey Moser was appointed as Chief Customer Officer, with the appointment announced on June 17, 2026 as part of organizational changes. The appointment is accompanied by a comprehensive compensation package including $500,000 in RSU equity awards and $500,000 in cash retention awards with specific vesting schedules and severance acceleration provisions.
View raw filing on EDGAR →Allurion Technologies implemented a 1-for-15 reverse stock split, approved by stockholders at the December 2025 Annual Meeting, with the Charter Amendment filed on June 12, 2026 and effective June 17-18, 2026. This material corporate action affects the company's share structure, trading symbol, and terms of warrants and convertible securities.
View raw filing on EDGAR →The Company resubmitted a New Drug Application (NDA) to the FDA for relacorilant, a treatment for Cushing's syndrome. This is a material regulatory milestone for a biopharmaceutical company, as NDA resubmission represents progress toward potential commercialization of a key product candidate. However, it does not fit neatly into the more specific event categories (e.g., it is not an earnings release, M&A activity, or executive change), making "other_material" the most appropriate classification.
View raw filing on EDGAR →The Company entered into a Third Amended and Restated Operating Agreement on June 15, 2026, which amended the operating agreement to reflect the liquidation and dissolution of Series I and updated indemnification provisions. This represents a material structural change to the Company's organizational documents and governance framework.
View raw filing on EDGAR →Fiserv entered into an Underwriting Agreement on June 16, 2026, to issue €1 billion in senior notes (€500M due 2030 at 3.750% and €500M due 2034 at 4.250%) in a public offering expected to close June 23, 2026. While this is a debt issuance rather than a traditional M&A transaction, Item 1.01 ("Entry into a Material Definitive Agreement") captures material financing arrangements. The €1 billion aggregate principal amount and the formal underwriting structure with major investment banks (Citigroup, J.P. Morgan, TD, Wells Fargo) indicate materiality to investors assessing the company's capital structure and liquidity.
View raw filing on EDGAR →The filing discloses Odyssey Therapeutics' financial results for the three months ended March 31, 2026, with a press release furnished as Exhibit 99.1. This is a standard quarterly earnings announcement under Item 2.02, which is the designated Item for disclosure of results of operations and financial condition.
View raw filing on EDGAR →The company completed the sale of a Rare Pediatric Disease Priority Review Voucher (PRV) for $187.5 million in cash on June 17, 2026. This is a material asset sale generating substantial one-time cash proceeds. While it is a financial transaction, it does not fit the specific categories of debt issuance, dividend distribution, or dilutive issuance; it is best classified as a financial event (asset disposition) that does not fit a named category.
View raw filing on EDGAR →The filing discloses financial and operational results for the three months and year ended March 31, 2026, with a press release furnished as Exhibit 99.1. This is a standard earnings release disclosure under Item 2.02, reporting quarterly and annual financial results for a public company.
View raw filing on EDGAR →Magnachip entered into an At Market Issuance Sales Agreement (ATM) on June 17, 2026, authorizing the sale of up to $50 million in common stock shares through B. Riley Securities. ATM offerings are classic dilutive equity issuances that signal capital raising and potential shareholder dilution. The material nature is confirmed by the $50 million aggregate offering price and the company's stated use of proceeds for strategic growth initiatives in AI data centers and robotics.
View raw filing on EDGAR →This disclosure announces the effective registration and imminent completion of a spin-off separation of Midera Food Processing, Inc. from The Middleby Corporation. The filing sets the record date (June 26, 2026) and expected distribution date (July 6, 2026) for a pro rata distribution of Midera shares to Middleby shareholders. This constitutes a material change of control and disposition event that fundamentally restructures the registrant's ownership and operations, fitting the ma_activity classification for a material separation/spin-off transaction.
View raw filing on EDGAR →The filing's primary disclosure is the appointment of Matthew J. Koscal as a director and his concurrent assumption of the Chief Executive Officer role, effective June 15, 2026. While the section also addresses compensation updates and David Grizzle's transition from CEO to non-executive Chairman, the central event is Koscal's appointment to the Board and his succession to the CEO position, which is material to investors assessing leadership continuity and strategic direction.
View raw filing on EDGAR →The filing discloses a material compensatory arrangement: the Board approved a grant of 271,076 performance-based restricted stock units (PSUs) to CEO Dr. KR Sridhar on June 15, 2026, under the 2018 Equity Incentive Plan. The award is conditioned on objective revenue and margin targets through 2029 and includes a holding requirement through 2031, designed to retain the CEO and align his incentives with strategic growth priorities. This is a classic equity compensation disclosure under Item 5.02(e).
View raw filing on EDGAR →Acrivon held its Annual Meeting of Stockholders and disclosed voting results for three proposals: election of two Class I directors (Michael Tomsicek and Charles Baum), ratification of PricewaterhouseCoopers LLP as independent auditor, and approval of the Amended and Restated 2022 Equity Incentive Plan. All three proposals passed with substantial majorities.
View raw filing on EDGAR →TTM Technologies announced entry into definitive stock purchase agreements to acquire two European companies—Swiss Technology Group AG and ILFA GmbH—in separate all-cash transactions subject to regulatory approval. The press release emphasizes these acquisitions as establishing TTM's initial European footprint and adding strategic PCB and materials capabilities across Medical, Aerospace & Defense markets. This is a material acquisition activity disclosed under Item 8.01 (Other Events) with expected close in Q3 2026.
View raw filing on EDGAR →The company appointed Chris Hyder as Executive Vice President and Chief Operating Officer and Nina Barton as Executive Vice President and Chief Growth & Strategy Officer, both effective June 17, 2026. These material C-suite appointments include compensatory arrangements (salary increases and RSU grants) and reflect significant changes to the company's executive leadership structure.
View raw filing on EDGAR →The 6-K discloses the results of an Annual Meeting of Shareholders held on June 16, 2026, with detailed voting tallies for eight proposals including director re-elections (Sam Moed, Yael Margolin, Adi Raviv), amendments to Articles of Association, CEO employment agreement amendment, equity grants to the CEO and Chairman, and auditor appointment. This is a classic shareholder_vote_results disclosure under Item 5.07 equivalent, and the outcomes are material to investors as they confirm board composition, executive compensation arrangements, and auditor selection.
View raw filing on EDGAR →The press release announces that Wing Yip Food Holdings has regained compliance with Nasdaq Listing Rule 5550(a)(2) after previously falling below the US$1.00 minimum bid price requirement on December 22, 2025. This disclosure directly addresses a delisting risk — the company was non-compliant with a continued listing standard and faced potential delisting, but has now cured the deficiency. The resolution of a delisting-risk event is material to investors assessing the registrant's continued exchange listing status.
View raw filing on EDGAR →This announcement discloses the final results of a tender offer for VEON MidCo B.V.'s outstanding 3.375% Notes due 2027. The Company accepted U.S.$886,075,000 in principal amount of tendered notes for cash, reducing outstanding debt from U.S.$1,013,973,000 to U.S.$124,898,000. While technically a debt reduction rather than issuance, the tender offer represents a material modification of the Company's direct financial obligations and capital structure, warranting classification under debt-related activity. The materiality is evident from the scale of the transaction (approximately 87% of outstanding notes retired) and its impact on the registrant's leverage profile.
View raw filing on EDGAR →